Literature DB >> 66240

Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer.

W T Beaver, S L Wallenstein, R W Houde, A Rogers.   

Abstract

The relative analgesic potency of oral and intramuscular oxymorphone was evaluated in a double-blind crossover comparison of graded single doses in patients with chronic pain due to cancer. When both duration and intensity of analgesia are considered (total effect), oral oxymorphone was 1/6 as potent as the intramuscular form. In terms of peak effect, however, oral oxymorphone was only 1/14 as potent. These values are almost identical to those obtained in a previous study comparing oral with intramuscular morphine. The analgesic effect of oral oxymorphone rose to a peak later and had a longer duration than the effect of intramuscular oxymorphone. Intramuscular oxymorphone and morphine were also compared in a similar patient group. Intramuscular oxymorphone proved to be 8.7 times as potent as morphine in terms of total analgesic effect and 13 times as potent in terms of peak effect. In roughly equinalgesic doses, the occurrence of side effects was qualitatively and quantitatively similar for oral and intramuscular oxymorphone and for intramuscular oxymorphone and morphine.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 66240     DOI: 10.1177/009127007701700402

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  14 in total

Review 1.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

Review 2.  Advances in opioid therapy and formulations.

Authors:  Declan Walsh
Journal:  Support Care Cancer       Date:  2004-12-14       Impact factor: 3.603

Review 3.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 5.  Oral morphine for cancer pain.

Authors:  Philip J Wiffen; Bee Wee; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-04-22

Review 6.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

7.  Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers.

Authors:  M R Lofwall; D E Moody; W B Fang; P A Nuzzo; S L Walsh
Journal:  J Clin Pharmacol       Date:  2011-05-24       Impact factor: 3.126

8.  Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.

Authors:  Lillian Huang; Stephen R Edwards; Maree T Smith
Journal:  Pharm Res       Date:  2005-07-29       Impact factor: 4.200

9.  Pharmacodynamic effects of oral oxymorphone: abuse liability, analgesic profile and direct physiologic effects in humans.

Authors:  Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Sharon L Walsh
Journal:  Addict Biol       Date:  2014-07-31       Impact factor: 4.280

10.  Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions.

Authors:  Hazem E Hassan; Susan L Mercer; Christopher W Cunningham; Andrew Coop; Natalie D Eddington
Journal:  Int J Pharm       Date:  2009-04-05       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.